Intravesical chemotherapy: studies on the relationship between osmolality and cytotoxicity
- PMID: 3090275
- DOI: 10.1016/s0022-5347(17)44880-4
Intravesical chemotherapy: studies on the relationship between osmolality and cytotoxicity
Abstract
The effectiveness of intravesical chemotherapy for the treatment of superficial bladder cancer may be influenced by the conditions of administration, such as the osmotic strength of the instillate. Urine from patients with bladder cancer before treatment had osmolalities in the range 187 to 852 mOsm./kg. and these had decreased by an average of 135 mOsm./kg. at the completion of intravesical chemotherapy. Clinical preparations of drugs used for intravesical chemotherapy had osmotic strengths ranging from 65 to 1,038 mOsm./kg. The antitumor activities of the drugs most frequently used intravesically (doxorubicin, epodyl, mitomycin C and thiotepa), and of cisplatin and epirubicin in media of 6 different osmolalities were measured with a human bladder cancer cell line by inhibition of colony-forming ability. Reducing osmotic strength from 590 to 125 mOsm./kg. significantly increased the in vitro cytotoxicities of thiotepa, mitomycin C, cisplatin and epirubicin but not those of doxorubicin and epodyl. We conclude that the use of an instillate at the lowest achievable osmotic strength probably will be optimal for the intravesical administration of chemotherapeutic drugs.
Similar articles
-
Intravesical chemotherapy. Studies on the relationship between pH and cytotoxicity.Cancer. 1986 Sep 15;58(6):1199-203. doi: 10.1002/1097-0142(19860915)58:6<1199::aid-cncr2820580604>3.0.co;2-z. Cancer. 1986. PMID: 3091241
-
Intravesical chemotherapy: in vitro studies on the relationship between dose and cytotoxicity.Urol Res. 1986;14(3):137-40. doi: 10.1007/BF00255832. Urol Res. 1986. PMID: 3092427
-
Intravesical chemotherapy: combination with Tween 80 increases cytotoxicity in vitro.Urol Res. 1987;15(1):17-20. doi: 10.1007/BF00256329. Urol Res. 1987. PMID: 3103302
-
Treatment of superficial bladder cancer with intravesical chemotherapy.Semin Surg Oncol. 1997 Sep-Oct;13(5):335-41. doi: 10.1002/(sici)1098-2388(199709/10)13:5<335::aid-ssu7>3.0.co;2-e. Semin Surg Oncol. 1997. PMID: 9259089 Review.
-
Complications of intravesical chemotherapy.Urol Clin North Am. 1992 Aug;19(3):529-39. Urol Clin North Am. 1992. PMID: 1636237 Review.
Cited by
-
Pharmacological principles of intraperitoneal and bidirectional chemotherapy.Pleura Peritoneum. 2017 Jun 1;2(2):47-62. doi: 10.1515/pp-2017-0010. Epub 2017 Apr 29. Pleura Peritoneum. 2017. PMID: 30911633 Free PMC article. Review.
-
ThioTEPA pharmacokinetics during intravesical chemotherapy and the influence of Tween 80.Cancer Chemother Pharmacol. 1990;25(4):267-73. doi: 10.1007/BF00684884. Cancer Chemother Pharmacol. 1990. PMID: 1688515 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical